source
- Genentech signs up to develop Alector’s preclinical blood-brain barrier therapy in $1.27 billion dealGenentech, a Roche subsidiary, announced a deal with Alector to obtain exclusive rights to its preclinical blood-brain barrier delivery asset, AL050. The agreement provides $100 million upfront an…
- FDA urged to boost US access to new and experimental drugs as trials shift to ChinaThe piece highlights that the FDA has taken steps such as launching Operation TrialBlazer and tightening review of foreign clinical data, but argues that further action is required to keep the Unit…